Leading Factors of Progression in Patients with Cardiac Amyloidosis

Aim. To describe prognostic meaning of cardiac and other principal clinical manifestations of systemic AL-amyloidosis in their interrelations.
Material and methods. It has been made long-time survival analysis of 147 patients with systemic AL-amyloidosis. In the special investigation group (n=58) of AL (n=55) and ATTR (n=3) amyloidotic cardiopathy patients there were evaluated prognostically important structural and functional changes in myocardium with standard and impulse-wave tissue dopplerometric echocardiography in comparison with NTproBNP serum levels.
Results. Even though significantly increased nowadays surviving of AL-amylodotic patients (Me=90 months) it has been found that as at previously time orthostatic hypotension and amyloid cardiopathy are being most severe initial syndromes (median 25 months), but after 1 year from diagnosis influence of these syndromes on surviving had decreased and most low surviving was more common in patients with CKD 3-5 (median 28 months). Influence of CKD 3-5 on surviving was associated predominantly with intracardial hemodynamics deterioration. Together with decreased systolic shortening strain rate (48,5%) decreased filtration rate (47,9%) was second of main factors contributing into NTproBNP increasing in effective multiple regression model (R=0,702, F(4,21)=5,095, p=0,005). NTproBNP level in less degree depended on renal clearance.
Conclusion. Heart damage is one of the most prognostically unfavorable manifestations of systemic amyloidosis due to a sharp deterioration in the elastic properties of the myocardium, in the process of further development of amyloidosis, the leading factor in progression is the deterioration of the profile of cardiorenal interactions, the marker of which is the level of NTproBNP.

1. Rosenzweig M, Landau H. Light chain (AL) amyloidosis: update on diagnosis and management. J Hematol Oncol. 2011;47(4). DOI:10.1186/1756-8722-4-47.

2. Kyle R, Gertz M. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45-59.

3. Patel KS, Hawkins PN. Cardiac amyloidosis: where are we today? J Intern Med. 2015; 278(2):126-44. DOI:10.1111/joim.12383.

4. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203-12. DOI:10.1161/CIRCULATIONAHA.108.843334.

5. Obici L, Perfetti V, Palladini G, et al. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005;1753(1):11-22. DOI:10.1016/j.bbapap.2005.08.014.

6. Rameev VV. Nowadays methods of the inheritant transthyretin amyloidosis diagnosis and treatment. Manage Pain. 2018;(1):20-4 (In Russ.)

7. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):375177. DOI:10.1200/JCO.2004.03.029.

8. Dittrich T, Kimmich C, Hegenbart U, Schönland SO. Prognosis and Staging of AL Amyloidosis. Acta Haematol 2020;143:388-399. DOI:10.1159/000508287.

9. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989-95. DOI:10.1200/JCO.2011.38.5724.

10. Palladini G, Foli A, Milani P, et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol. 2012;87(5):465-71. DOI:10.1002/ajh.23141.

11. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97(1):75-84. DOI:10.1136/hrt.2009.190405.

12. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4):319-28.

13. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-70. DOI:10.1093/ehjci/jev014.

14. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277-314. DOI:10.1016/j.echo.2016.01.011.

15. Muchtar E, Dispenzieri A, Magen H, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2021;289(3):268-92. DOI:10.1111/joim.13169.

16. Mavrogeni SI, Vartela V, Ntalianis A, et al. Cardiac amyloidosis: in search ofthe ideal diagnostic tool. Herz. 2021;46(Suppl 1):S9-S14. DOI:10.1007/s00059-019-04871-5.

17. Rezk T, Lachmann HJ, Fontana M, et al. Cardiorenal AL amyloidosis: risk stratification and outcomesbased upon cardiac and renal biomarkers. Br J Haematol. 2019;186(3):460-77. DOI:10.1111/bjh.15955.

18. Gudkova A Ya, Lapekin SV, Bezhanashvili TG, et al. The AL-amyloidosis with predominant cardiac involvement. An algorithm for noninvasive diagnostics of amyloidotic cardiomyopathy. Ter Arkhiv. 2021;93(4):487-96 (In Russ.) DOI:10.26442/00403660.2021.04.200689.